Abstract：Objective: To analyze the efficacy and safety of olanzapine tablets combined with clomipramine in the treatment of refractory obsessive-compulsive disorder. Methods: 176 patients with refractory obsessive-compulsive disorder who treated from January 2014 to January 2018 in our hospital, according to simple random method those patients were divided into control group (n=81) and observation group (n=95) , the control group was treated with chlorpromizide, and the observation group was treated with olanzapine tablets on the basis of the control group. Then clinical efficacy, Yale-Brown Forced Scale (YBOCS), Hamilton Anxiety Scale (HAMA), and Hamilton Depression Scale (HAMD) scores, quality of life scores, blood routine, liver and kidney function at different time points before and after treatment, and adverse reactions in both group were compared. Results: The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). Before treatment, YBOCS, HAMA and HAMD scores, quality of life scores, blood routine and liver and kidney functions in both group were no statistically different (P>0.05). There were significant differences in YBOCS, HAMA, HAMD and quality of life scores between the two groups in different treatment methods and treatment time (P<0.05). Blood routine and liver and kidney functions in the groups were no significantly changed, there were no statistically significant differences (P>0.05). the incidence of adverse reactions in th both groups was no statistical difference (P>0.05). Conclusion: Olanzapine combined with clomipramine has synergistic effect on the treatment of refractory obsessive-compulsive disorder, which can effectively improve the symptoms of patients, improve the quality of life, and tolerate side effects.
刁维东, 王金柱, 李永红. 奥氮平片联合氯丙咪嗪治疗难治性强迫症的疗效及对安全性分析[J]. 河北医学, 2019, 25(5): 823-827.
DIAO Weidong, WANG Jinzhu, LI Yonghong. Analysis of Curative Effect and Safety of Olanzapine Tablets combined with Chlorpromizide in the treatment of Refractory Obsessive-compulsive Disorder. HeBei Med, 2019, 25(5): 823-827.
[1] Kazhungil F, Mohandas E. Management of obsessive-compulsive disorder comorbid with bipolar disorder[J]. Indian Psychiatry, 2016,58(3):259~269. [2] 司天梅.中国强迫症防治指南2016解读:药物治疗[J].中华精神科杂志,2017,50(4):249~252. [3] 中华医学会精神医学分会《中国强迫症防治指南》编写组.中国强迫症防治指南2016(精编版)[J].中华精神科杂志,2016,49(6):353~366. [4] 郭艳红,孙祥虹.重复经颅磁刺激并药物治疗难治性强迫症的效果[J].齐鲁医学杂志,2017,32(3):338~341. [5] 丘春柳.新型与传统抗强迫药物治疗强迫症2年效果随访对照研究[J].临床和实验医学杂志,2015,14(15):1259~1262. [6] Amerio A, Tonna M, Odone A, et al. Treatment of comorbid bipolar disorder and anxiety disorders: A great challenge to modern psychiatry[J]. Aust N Z Psychiatry,2016,50(7):699~700. [7] 吴爱靖,安琦,乔素婷.帕罗西汀与氯丙咪嗪治疗强迫症的比较[J].中国组织工程研究,2016,20(b5):85~86. [8] Albert U, Carmassi C, Cosci F, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review[J]. Int Clin Psychopharmacol,2016,31(5):249~258. [9] Figueiredo T, Segenreich D, Mattos P. Fluoxetine adjunctive therapy for obsessive-compulsive symptoms associated with olanzapine in schizophrenic patients[J].Clin Psychopharmacol,2016,36(4):389~391. [10] 战玉华,韩继阳,邵云,等.帕利哌酮缓释片联合选择性5-羟色胺再摄取抑制剂治疗难治性强迫障碍疗效观察[J].实用药物与临床,2016,19(7):889~892. [11] 景兰.奥氮平联合艾司西酞普兰治疗难治性强迫症的疗效分析[J].安徽医药,2017,18(4):653~655. [12] Sahoo P, Sethy RR, Ram D. Functional impairment and quality of life in patients with obsessive compulsive disorder[J]. Indian Psychol Med,2017 ,39(6):760~765.
2019, Vol. 25 
冀公网安备13080202000677号